DK1247522T3 - Polyetherestercopolymerer som grundmasser til afgivelse af lægemidler - Google Patents

Polyetherestercopolymerer som grundmasser til afgivelse af lægemidler

Info

Publication number
DK1247522T3
DK1247522T3 DK02077025T DK02077025T DK1247522T3 DK 1247522 T3 DK1247522 T3 DK 1247522T3 DK 02077025 T DK02077025 T DK 02077025T DK 02077025 T DK02077025 T DK 02077025T DK 1247522 T3 DK1247522 T3 DK 1247522T3
Authority
DK
Denmark
Prior art keywords
drug delivery
bases
polyetherester copolymers
polyetherester
glycol
Prior art date
Application number
DK02077025T
Other languages
English (en)
Inventor
Jacob Hildebrand Goedemoed
Wilhelmus Everhardus Hennink
Jeroen Mattijs Bezemer
Jan Feijen
Blitterswijk Clemens Van
Bruijn Joost Dick De
Original Assignee
Chienna Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chienna Bv filed Critical Chienna Bv
Application granted granted Critical
Publication of DK1247522T3 publication Critical patent/DK1247522T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
DK02077025T 1996-08-16 1997-08-18 Polyetherestercopolymerer som grundmasser til afgivelse af lægemidler DK1247522T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/699,896 US5980948A (en) 1996-08-16 1996-08-16 Polyetherester copolymers as drug delivery matrices
EP97202533A EP0830859B1 (en) 1996-08-16 1997-08-18 Polyetheresters copolymers as drug delivery matrices

Publications (1)

Publication Number Publication Date
DK1247522T3 true DK1247522T3 (da) 2004-09-27

Family

ID=24811379

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97202533T DK0830859T3 (da) 1996-08-16 1997-08-18 Polyetherestercopolymere som lægemiddelafgivelsesmatricer
DK02077025T DK1247522T3 (da) 1996-08-16 1997-08-18 Polyetherestercopolymerer som grundmasser til afgivelse af lægemidler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK97202533T DK0830859T3 (da) 1996-08-16 1997-08-18 Polyetherestercopolymere som lægemiddelafgivelsesmatricer

Country Status (9)

Country Link
US (1) US5980948A (da)
EP (2) EP1247522B1 (da)
AT (2) ATE267006T1 (da)
CA (1) CA2213368C (da)
DE (2) DE69726672T2 (da)
DK (2) DK0830859T3 (da)
ES (2) ES2221916T3 (da)
PT (2) PT830859E (da)
WO (1) WO1998006439A1 (da)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (en) * 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
FR2777895A1 (fr) 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6656489B1 (en) 1999-02-10 2003-12-02 Isotis N.V. Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material
EP1038538A1 (en) * 1999-03-19 2000-09-27 IsoTis B.V. Muscle tissue engineering
AU3957400A (en) * 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
EP1068872A1 (en) * 1999-07-12 2001-01-17 IsoTis B.V. Sutures
AU4518400A (en) * 1999-07-12 2001-01-18 Isotis B.V. Sutures
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
DE60043630D1 (de) * 1999-08-06 2010-02-11 Chienna Bv Formung eines Polymers
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
EP1090928B1 (en) * 1999-09-30 2004-05-26 Chienna B.V. Polymers loaded with bioactive agents
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
DE60127139T2 (de) * 2000-07-14 2007-12-13 Novo Nordisk A/S Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial
EP1247537A1 (en) * 2001-04-04 2002-10-09 Isotis B.V. Coating for medical devices
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
US6565884B2 (en) 2001-09-10 2003-05-20 Interpore Cross International Bone graft material incorporating demineralized bone matrix and lipids
AU2002343681B2 (en) * 2001-11-12 2006-07-06 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
ATE335035T1 (de) * 2002-02-26 2006-08-15 Chienna Bv Bioabbaubares polymermaterial für biomedizinische anwendungen
EP2561860B1 (en) * 2002-05-31 2018-02-28 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
MXPA05010450A (es) * 2003-03-31 2005-11-04 Titan Pharmaceuticals Inc Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20040215318A1 (en) * 2003-04-24 2004-10-28 Brian Kwitkin Timed delivery of therapeutics to blood vessels
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
WO2005094553A2 (en) * 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Compositions for promoting bone growth and methods thereof
WO2005097223A1 (en) 2004-03-26 2005-10-20 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7311980B1 (en) * 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
US7816320B2 (en) 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
ATE542920T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
US20060147491A1 (en) * 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
EP1679065A1 (en) 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
CN103030690A (zh) * 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
KR101285904B1 (ko) 2005-08-18 2013-07-15 암브룩스, 인코포레이티드 ｔＲＮＡ 조성물 및 이의 용도
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
US20090018029A1 (en) * 2005-11-16 2009-01-15 Ambrx, Inc. Methods and Compositions Comprising Non-Natural Amino Acids
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
CN105384807A (zh) * 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
EP2037977A2 (en) * 2006-06-28 2009-03-25 SurModics, Inc. Active agent eluting matrices with particulates
SG174781A1 (en) * 2006-09-08 2011-10-28 Ambrx Inc Hybrid suppressor trna for vertebrate cells
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
JP5451390B2 (ja) * 2006-09-08 2014-03-26 アンブルックス，インコーポレイテッド 脊椎動物細胞内におけるサプレッサーｔｒｎａの転写
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US20080293637A1 (en) 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
US8709827B2 (en) * 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
US8137661B2 (en) * 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9138509B2 (en) * 2007-09-14 2015-09-22 Musculoskeletal Transplant Foundation Composition for filling bone defects
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP2055299A1 (en) * 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Methods for preparing polymer microparticles
SI2818184T1 (sl) 2007-11-16 2019-03-29 Aclaris Therapeutics, Inc. Sestava in postopki za zdravljenje purpure
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
DE102007062113B4 (de) * 2007-12-21 2011-05-12 Bettina Lingenfelder Dermatologische Zubereitung
EP2235266A1 (en) * 2007-12-21 2010-10-06 3M Innovative Properties Company Retroreflective pavement markings
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EP2242520A2 (en) * 2008-01-14 2010-10-27 SurModics, Inc. Devices and methods for elution of nucleic acid delivery complexes
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
CA2719222C (en) 2008-03-28 2018-07-24 Surmodics, Inc. Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
WO2009126830A2 (en) * 2008-04-09 2009-10-15 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
EP2265293B1 (en) * 2008-04-18 2015-11-04 SurModics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
EP2756756B1 (en) 2008-04-28 2016-01-06 Zogenix, Inc. Novel formulations for treatment of migraine
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
WO2010009122A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
AU2009288118B2 (en) 2008-09-02 2014-12-11 Allergan, Inc. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
AU2009296267B2 (en) 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
CA2758260A1 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
US8883208B2 (en) * 2009-04-08 2014-11-11 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
US8246576B2 (en) 2009-05-18 2012-08-21 Surmodics, Inc. Method and apparatus for delivery of a therapeutic agent with an expandable medical device
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
EP2544652A2 (en) 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
HUE043344T2 (hu) 2010-03-22 2019-08-28 Allergan Inc Térhálósított hidrogélek lágy szövet növelésére
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
CA2804601C (en) 2010-07-09 2020-05-19 Innocore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012042314A1 (en) 2010-10-02 2012-04-05 Link Research & Grants Corporation Treatment of tinnitus and related auditory dysfunctions
WO2012058274A2 (en) 2010-10-26 2012-05-03 Surmodics, Inc. Coatings and methods for controlled elution of hydrophilic active agents
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
RU2624239C2 (ru) 2011-06-03 2017-07-03 Аллерган, Инк. Составы кожного наполнителя, включая антиоксиданты
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
WO2013012924A2 (en) 2011-07-18 2013-01-24 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
RU2018125698A (ru) 2011-07-22 2019-03-13 Иннокор Текнолоджис Б.В. Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (da) 2012-06-26 2017-01-23 Sutro Biopharma Inc Modificerede fc-proteiner, der omfatter stedsspecifikke ikke-naturlige aminosyrerester, konjugater heraf, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
WO2014071387A1 (en) 2012-11-05 2014-05-08 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
FR3007972B1 (fr) 2013-07-04 2015-08-07 Oreal Composition cosmetique comprenant des esters gras liquides, des huiles volatiles et des epaississants, et procede de traitement cosmetique
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3912986B1 (en) 2013-12-18 2023-12-13 President and Fellows of Harvard College Crp capture/detection of bacteria
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
US10519443B2 (en) 2014-09-08 2019-12-31 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
ES2761558T3 (es) 2014-09-30 2020-05-20 Allergan Ind Sas Composiciones de hidrogel estables que incluyen aditivos
KR102637699B1 (ko) 2014-10-24 2024-02-19 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
CN108289928A (zh) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
RU2020123343A (ru) 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для омоложения кожи
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
EP3923991A1 (en) 2019-02-12 2021-12-22 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
ATE168391T1 (de) * 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
FR2671562B1 (fr) * 1991-01-16 1995-09-15 Oreal Procede de diagnostic d'un etat d'inflammation ou de vieillissement cellulaire des keratinocytes, et necessaire pour la mise en óoeuvre de ce procede.
DE69329594T2 (de) * 1992-02-28 2001-05-31 Univ Texas Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
JPH07505813A (ja) * 1992-04-24 1995-06-29 オステオテク，インコーポレイテッド 組織癒着予防装置
ES2095001T5 (es) * 1992-12-22 2001-03-16 Univ Cincinnati Una composicion terapeutica administrable oralmente y su metodo de obtencion.
BR9407397A (pt) * 1993-07-12 1996-11-05 Virus Res Inst Vacinas microencapsuladas em hidrogel
DE69524398T2 (de) * 1994-04-08 2002-07-18 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
EP0717999A1 (en) * 1994-12-19 1996-06-26 The University Of Miami Drug delivery composition

Also Published As

Publication number Publication date
DK0830859T3 (da) 2004-04-05
ES2212037T3 (es) 2004-07-16
CA2213368A1 (en) 1998-02-16
EP0830859B1 (en) 2003-12-10
EP0830859A2 (en) 1998-03-25
US5980948A (en) 1999-11-09
EP0830859A3 (en) 1998-07-22
ATE255884T1 (de) 2003-12-15
ATE267006T1 (de) 2004-06-15
DE69726672D1 (de) 2004-01-22
DE69729228T2 (de) 2005-05-04
DE69726672T2 (de) 2004-10-07
DE69729228D1 (de) 2004-06-24
EP1247522A1 (en) 2002-10-09
PT1247522E (pt) 2004-10-29
PT830859E (pt) 2004-04-30
EP1247522B1 (en) 2004-05-19
WO1998006439A1 (en) 1998-02-19
CA2213368C (en) 2008-04-01
ES2221916T3 (es) 2005-01-16

Similar Documents

Publication Publication Date Title
DK1247522T3 (da) Polyetherestercopolymerer som grundmasser til afgivelse af lægemidler
CA2355657A1 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
ZA9811377B (en) Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
WO2003091337A8 (en) New polyarylates for drug delivery and tissue engineering
BR9801027B1 (pt) sistema de distribuiÇço de medicamentos.
NO995313L (no) Mikroartikler nyttige som ultrasoniske kontrastmidler og til levering av legemidler i blodbanen
DE69823055D1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
HUP0102803A2 (hu) Hőérzékeny és biológiailag lebontható hidrogélek biológiailag aktív anyagok elnyújtott idejű felszabadulásának biztosítására
BRPI0013439B1 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
ATE291417T1 (de) Gastrointestinales wirkstoffverabreichungssystem
PL350552A1 (en) Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
ZA200204603B (en) Amphiphilic polymers and polypeptide conjugates comprising same.
ATE412403T1 (de) Biologisch abbaubare gemischte polymerische mizellen zur genverabreichung
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
WO2004011524A3 (en) Sulfonated aliphatic-aromatic copolyetheresters
BR9812553B1 (pt) formulação medicamentosa em pélete de difusão controlada e em um sistema matriz.
EP0613910A3 (de) Polymethacrylsäureester, deren Estergruppen in alpha- und gegebenenfalls zusätzlich in omega-Stellung von den in der Kette befindlichen Estergruppen abweichen.
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
BR9810285A (pt) Solução, composição farmacêutica, e, cápsula de gelatina.
HUP0001458A3 (en) Specific pancreatic lipase inhibitor peptides, pharmaceutical compositions and diagnostical reagents comprising thereof and their applications
USD448427S1 (en) Card game
ID29586A (id) ((aminoiminometil)amino) alkanakarboksamida-((aminoiminometil)amino) alkanakarboksamida dan aplikasi-aplikasinya dalam terapi
AU2002251955A1 (en) Biodegradable cationic copolymers of poly(alkylenimine) and poly(ethylene glycol) for the delivery of bioactive agents
DK1304105T3 (da) Implanterbart diffusionsafleveringssystem
IT1298064B1 (it) Sistema mobile audio video per mezzi pubblici, in particolare per la diffusione di messaggi istituzionali, sociali e pubblicitari.